Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of FCR versus FCCam in previously untreated Binet stage B and C B-CLL
2007-000327-18Phase 3Completed
- Sponsor
- Goelams
- Start
- Apr 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of alemtuzumab and rituximab in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (2 arms), sponsored by Goelams. Primary endpoint: progression-free survival at 36 months. Started Apr 2007; status: completed.
02
Drugs
alemtuzumabrituximab
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2007-000327-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000327-18.